Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
SINGULAR GENOMICS SYSTEMS Aktie jetzt für 0€ handeln | |||||
27.02. | Singular Genomics Systems, Inc. - 8-K, Current Report | - | SEC Filings | ||
21.02. | Singular Genomics Systems Completes Acquisition By Deerfield Management | - | RTTNews | ||
21.02. | Singular Genomics Systems, Inc.: Singular Genomics Announces Closing of Acquisition by Deerfield Management | 168 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower... ► Artikel lesen | |
21.02. | NSE - Singular Genomics Systems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
13.02. | Singular Genomics Systems, Inc. - 8-K, Current Report | - | SEC Filings | ||
23.12.24 | Singular Genomics Systems, Inc.: Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share | 751 | GlobeNewswire (Europe) | SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and... ► Artikel lesen | |
19.09.24 | Singular Genomics Systems, Inc.: Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital | 347 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower... ► Artikel lesen | |
13.09.24 | Pre-market Movers: Tenon Medical, Vision Marine Technologies, SMX, Singular Genomics Systems, Immuneering | 1.156 | AFX News | SAN JOSE (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).In the Green Tenon Medical, Inc. (TNON) is up over 350% at $19.80.
Vision... ► Artikel lesen | |
12.09.24 | Singular Genomics Systems, Inc.: Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield | 247 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 92,95 | -0,32 % | Novo Nordisk, BioNxt Solutions, BioNTech - so heilen Sie Ihr Portfolio mit der Gesundheits-Revolution 2025 | Das globale Gesundheitswesen erlebt 2025 eine Zeitenwende. Klimafolgen, chronische Krankheiten und Pandemienarben fordern Systeme heraus, während Digitalisierung und KI rasant neue Therapien vorantreiben.... ► Artikel lesen | |
EVOTEC | 6,150 | -17,52 % | Evotec-Aktie mit Kursgewinnen (7,346 €) | Im Plus liegt derzeit der Anteilsschein von Evotec . Das Papier kostete zuletzt 7,35 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Evotec zwischenzeitlich um 3,41 Prozent verteuert.... ► Artikel lesen | |
VALNEVA | 2,636 | -0,83 % | Valneva Aktie zündet nach Impfstoff-News - oder doch nur ein Strohfeuer? | Die Valneva Aktie reagierte am Montag mit einem Kurssprung auf die Meldung, dass die Europäische Arzneimittel-Agentur EMA nach positiver Prüfung die Altersbeschränkung für den Chikungunya-Impfstoff... ► Artikel lesen | |
NOVAVAX | 6,096 | -0,68 % | UNGLAUBLICHE Sondermeldung bei Novavax Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
MAINZ BIOMED | 2,110 | +11,05 % | EQS-News: Mainz BioMed N.V.: Mainz Biomeds Update für das erste Halbjahr 2025: Beschleunigung des Wegs zur FDA-Zulassung für Darmkrebstest der nächsten Generation und Portfolio-Erweiterung durch Erwerb im Bereich Pankreaskrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomeds Update für das erste Halbjahr 2025: Beschleunigung des Wegs zur FDA-Zulassung für Darmkrebstest... ► Artikel lesen | |
BAVARIAN NORDIC | 24,690 | 0,00 % | Bavarian Nordic A/S: Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine | COPENHAGEN, Denmark, July 22, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company's application for licensure of the single-dose, virus-like... ► Artikel lesen | |
BIOMARIN PHARMACEUTICAL | 48,340 | -1,81 % | BioMarin: Wolfe Research bestätigt Outperform-Rating trotz neuer Konkurrenz im PKU-Markt | ||
MEREO BIOPHARMA | 1,420 | -2,74 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis | NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled... ► Artikel lesen | |
SIGA TECHNOLOGIES | 6,850 | +3,71 % | Dividendenbekanntmachungen (15.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 1&1 AG DE0005545503 - 0,05 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0536 EUR ADMIRAL GROUP PLC GB00B02J6398 0,914 GBP 1,0846... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
ITEOS THERAPEUTICS | 10,135 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,040 | +0,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 26,340 | +0,53 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
SAB BIOTHERAPEUTICS | 2,655 | 0,00 % | SAB Biotherapeutics: Oppenheimer erhöht Kursziel auf 14 US-Dollar |